Magenta Therapeutics, Inc. operates as a bio-technology company. The Company develops medicines, molecules, and cell therapy to transform patient preparation, stem cell expansion, and stem cell harvesting, as well as reduces post-transplant complications. Magenta Therapeutics serves patients in the State of Massachusetts.

Current report pursuant to Section 13 or 15(d) (PDF)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Magenta Therapeutics Inc (MGTA US)

Current report pursuant to Section 13 or 15(d) (PDF)

Current report pursuant to Section 13 or 15(d) (PDF)

US SEC Form 425 for Magenta Therapeutics Inc

General form for quarterly reports under Section 13 or 15(d) (PDF)

US SEC Form 424B3 for Magenta Therapeutics Inc

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)